Immune System News and Research

RSS

Researchers evaluate dental pulp cells as optimal source of iPS cells

Defined sets of factors can reprogram human cells to induced pluripotent stem cells. However, many types of human cells are not easily accessible to minimally invasive procedures. In a paper published in the International and American Associations for Dental Research's Journal of Dental Research, lead researcher K. Tezuka and researchers N. Tamaoki, H. Aoki, T. Takeda-Kawaguchi, K. Iida, T. Kunisada and T. Shibata all from the Gifu University Graduate School of Medicine, Japan; and K. Takahashi, T. Tanaka and S. Yamanaka, all from Kyoto University, Japan, evaluate dental pulp cells as an optimal source of iPS cells, since they are easily obtained from extracted teeth and can be expanded under simple culture conditions.

18 Jun 2010

One in three people with psoriasis do not receive proper treatment due to health insurance issues: Survey

Results from a new survey reveal that one in three people with psoriasis do not receive proper treatment for their disease due to health insurance issues—and many won't be helped by the new health care reform law.

17 Jun 2010

Biological mechanism associated with remission during pregnancy

During pregnancy, many women experience remission of autoimmune diseases like multiple sclerosis and uveitis. Now, scientists have described a biological mechanism responsible for changes in the immune system that helps to explain the remission.

17 Jun 2010

Scientific American publishes article on "rebirth" of DNA vaccines

Inovio Pharmaceuticals, Inc., a leader in the development of therapeutic and preventive vaccines against cancers and infectious diseases, announced today that Scientific American magazine has published in its July issue an article entitled "DNA Drugs Come of Age." The article was co-authored by Dr. David Weiner, Chairman, Scientific Advisory Board, Inovio Pharmaceuticals, and Professor, Department of Pathology & Laboratory Medicine, at the University of Pennsylvania and Dr. Matthew Morrow, a post-doctorate research fellow at University of Pennsylvania.

17 Jun 2010

VBL presents positive preclinical data on VB-201 for rheumatoid arthritis at EULAR

VBL Therapeutics, a clinical-stage biotechnology company committed to the development of novel treatments for immune-inflammatory diseases and cancer, today announced preclinical data demonstrating that VB-201 possesses anti-inflammatory properties and effectively reduced the symptoms of arthritis in experimental models.

17 Jun 2010

Implications for reducing clotting in kidney disease dialysis and sepsis

The interaction of the drug compstatin with two ancient, co-evolved human systems points to new ways for reducing clotting during dialysis for end-stage kidney disease and multiple organ failure due to sepsis, a dangerous whole-body inflammatory response to infection.

17 Jun 2010

Researchers assess effect of MDs on cardiac and endothelial cell proliferation, survival

A research team from McGill University (Canada) report a beneficial effect on cardiac function in mouse models when implanted monocytes - a type of white blood cell that is part of the immune system - helped preserve cardiac function following a heart attack (myocardial infarction).

17 Jun 2010

Researchers identify peptide that triggers diabetes

Researchers at National Jewish Health and the University of Colorado Anschutz Medical Campus have identified the precise protein fragment, or peptide, that can trigger diabetes in mice. The finding, published in the June 15, 2010, issue of the Proceedings of the National Academy of Sciences, supports an emerging theory about the origins of autoimmunity, and may lead to new diagnostic and therapeutic strategies in humans.

17 Jun 2010

CINJ researchers combine series of vaccination injections to treat prostate cancer

Looking to harness the body's own immune system to target prostate cancer that has spread to the bones (metastatic) and is unresponsive to standard treatment, investigators at The Cancer Institute of New Jersey have just launched a clinical trial focusing on a combination of vaccine and radiation drug therapy.

17 Jun 2010

Studies suggest role for IL-10 in prevention and treatment of neurological disease in newborns

This bacterium, Escherichia coli K1, is the most common cause of meningitis in premature infants and the second most common cause of the disease in newborns. "The ineffectiveness of antibiotics in treating newborns with meningitis and the emergence of antibiotic-resistant strains of bacteria require new strategies," explains Nemani V. Prasadarao, PhD, associate professor of infectious disease at Childrens Hospital Los Angeles.

17 Jun 2010

Experimental vaccine for Marburg hemorrhagic fever prevention shows promise for accidental exposures

An experimental vaccine developed to prevent outbreaks of Marburg hemorrhagic fever continues to show promise in monkeys as an emergency treatment for accidental exposures to the virus that causes the disease. There is no licensed treatment for Marburg infection, which has a high fatality rate.

17 Jun 2010

Researchers sequence genome of Amerindian strain of the gastric bug H. pylori

An international team of researchers led by scientists at the Virginia Bioinformatics Institute at Virginia Tech have sequenced the genome of an Amerindian strain of the gastric bug Helicobacter pylori, confirming the out-of-Africa migration of this bacterial stowaway to the New World. Experiments in animals have highlighted how specific genes in the bacterial strain may be crucial to the onset of inflammation and disease.

17 Jun 2010

New biomarker study explores early detection of ovarian cancer

Despite many research advances, ovarian cancer remains lethal in a majority of cases, due to late diagnosis of the disease. In a new study, Dr. Joshua LaBaer of the Biodesign Institute at Arizona State University, along with Arturo Ramirez and Paul Lampe, researchers at the Fred Hutchinson Cancer Research Center in Seattle, used a novel method for identifying biomarkers-proteins in blood that can identify ovarian cancer before symptoms appear.

17 Jun 2010

BD Biosciences further expands Research Grant program to support promising stem cell research

BD Biosciences, a segment of BD, announced today a further expansion of its Research Grant program, adding $100,000 worth of reagents, cell culture tools and labware to support promising stem cell research.

From BD (Becton, Dickinson and Company) 17 Jun 2010

AssureImmune merges with BCU

AssureImmune LLC, the premier family stem cell bank in the United States, today announced their merger with Banco de Cordón Umbilical, the largest cord blood bank in Latin America. This merger expands the Companies' global reach providing family stem cell banking services to North, Central and South America.

16 Jun 2010

Life Technologies forms GIBCO Cell Therapy Systems

Life Technologies Corporation today announced the formation of GIBCO® Cell Therapy Systems (CTS™), which will offer the life science industry's widest array of products to support cell therapy applications, including regenerative medicine. Specifically designed to help cell therapy practitioners accelerate the transition from research to clinical applications, the product portfolio will include a broad and deep offering of Invitrogen devices and reagents.

16 Jun 2010

Phase IIb EMBLEM study demonstrates clinical efficacy of epratuzumab in patients with SLE

UCB and Immunomedics Inc. announced new lupus drug candidate, epratuzumab, provided a significant reduction in disease activity in patients with moderate to severe active systemic lupus erythematosus (SLE). Data presented at the European League Against Rheumatism (EULAR) meeting in Rome from the phase IIb study, EMBLEM™, showed the clinical efficacy of epratuzumab in patients with SLE.

16 Jun 2010

Nuon Therapeutics NU1618 phase 2a study in hyperuricemia meets primary endpoint

Nuon Therapeutics, Inc., a privately held, clinical stage biopharmaceutical company, announced that a phase 2a study of NU1618, the company's lead program, met its primary endpoint of reduction in serum uric acid (sUA) levels in patients with hyperuricemia.

16 Jun 2010

Nordic Naturals introduces Omega Probiotic for optimal digestive and gastrointestinal health

Nordic Naturals, the industry leader in omega-3 fish oil, introduces Omega Probiotic, a synergistic blend of fish oil and live probiotic spores for optimal digestive and gastrointestinal health. The breakthrough formula combines two important nutrients that are commonly lacking in today's modern diet in one easy-to-take supplement that does not require refrigeration.

16 Jun 2010

Microneedle skin patches as effective as hypodermic needles for flu vaccination

Flu vaccine delivered through skin patches containing microneedles has proven at least as effective at preventing influenza in mice as intramuscular, hypodermic flu immunization.

16 Jun 2010

Immune System News and Research

Researchers evaluate dental pulp cells as optimal source of iPS cells

One in three people with psoriasis do not receive proper treatment due to health insurance issues: Survey

Biological mechanism associated with remission during pregnancy

Scientific American publishes article on "rebirth" of DNA vaccines

VBL presents positive preclinical data on VB-201 for rheumatoid arthritis at EULAR

Implications for reducing clotting in kidney disease dialysis and sepsis

Researchers assess effect of MDs on cardiac and endothelial cell proliferation, survival

Researchers identify peptide that triggers diabetes

CINJ researchers combine series of vaccination injections to treat prostate cancer

Studies suggest role for IL-10 in prevention and treatment of neurological disease in newborns

Experimental vaccine for Marburg hemorrhagic fever prevention shows promise for accidental exposures

Researchers sequence genome of Amerindian strain of the gastric bug H. pylori

New biomarker study explores early detection of ovarian cancer

BD Biosciences further expands Research Grant program to support promising stem cell research

AssureImmune merges with BCU

Life Technologies forms GIBCO Cell Therapy Systems

Phase IIb EMBLEM study demonstrates clinical efficacy of epratuzumab in patients with SLE

Nuon Therapeutics NU1618 phase 2a study in hyperuricemia meets primary endpoint

Nordic Naturals introduces Omega Probiotic for optimal digestive and gastrointestinal health

Microneedle skin patches as effective as hypodermic needles for flu vaccination

Understanding the DNA Damage Response in Innate Immunity eBook

How ELRIG Is Helping Mid-Career Scientists Navigate Leadership, Career Change and Redundancy

The role of UV-Vis in biopharma QC

Applications Engineer

Latest News